Xeris Biopharma exchanges ~69% of 8% Convertible Notes due 2028 for cash and stock

Xeris Biopharma Holdings, Inc.

Entered private exchange to retire ~$23M (69%) of 8% Convertible Senior Notes due 2028.
Exchange consideration: $23M cash plus shares based on 21-day VWAP; ~4.6M shares if price is $6.71.
After exchange, $10.5M notes remain outstanding; annual interest savings ~$2M.
Expected close around July 15, 2026; Morgan Stanley acted as placement agent.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Xeris Biopharma Holdings, Inc. issued common stock to certain holders (the "Noteholders") of its 8.00% Convertible Senior Notes due 2028 for approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company's common stock.

Security: common stock
Purchaser: certain holders (the "Noteholders") of its 8.00% Convertible Senior Notes due 2028
Consideration: approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company's common stock

Exact text from the filing

On June 10, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders (the “Noteholders”) of its 8.00% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which the Noteholders have agreed to exchange (the “Exchange”) approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company’s common stock (the “Exchange Consideration”).

View on SEC.gov

226 equity issuances filed in the last 30 days. Browse all equity issuances →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-26-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.